3D QSAR investigation of the blood-brain barrier penetration of chemical compounds

SAR and QSAR in Environmental Research

Volumn 16, Issue 1-2, 2005, Pages 79-91

  Lessigiarska, I ^a,b   Pajeva, I ^c   Cronin, M T D ^b   Worth, A P ^a  

^a JOINT RESEARCH CENTRE   (Italy)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c CENTRE OF BIOMEDICAL ENGINEERING   (Bulgaria)

Author keywords

3D QSAR; Blood brain barrier; Imipramine; Phenothiazine

Indexed keywords

BLOOD; COMPUTATIONAL CHEMISTRY; GLYCOPROTEINS; HYDROPHOBICITY; INSECTICIDES; PHOSPHOLIPIDS;

3D-QSAR; BARRIER PENETRATION; BLOOD-BRAIN BARRIER; CHEMICAL CLASS; IMIPRAMINE; MEMBRANE ACTIVITY; MULTIDRUG RESISTANCE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVES; TUMOUR CELLS;

GENETIC ALGORITHMS;

EID: 18244374478     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629360412331319817     Document Type: Conference Paper

References (17)

1. Pajeva, I.K., Wiese, M., Cordes, H.P. and Seydel, J.K. (1996) "Membrane interactions of some catamphiphilic drugs and relation to their multidrug resistance reversing ability", J. Cancer Res. Clin. Oncol. 122, 27-40.
2. Ford, J.M., Prozialeck, W.C. and Hait, W.N. (1989) "Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance", Mol. Pharmacol. 35, 105-115.
3. Ramu, A. and Ramu, N. (1992) "Reversal of multidrug resistance by phenothiazines and structurally related compounds", Cancer Chemother. Pharmacol. 30, 165-173.
4. Pajeva, I.K. and Wiese, M. (1998) "Molecular modelling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study", J. Med. Chem. 41, 1815-1826.
5. Wiese, M. and Pajeva, I.K. (2001) "Structure-activity relationships of multidrug resistance reversers", Curr. Med. Chem. 8, 685-713.
6. Platts, J.A., Abraham, M.H., Zhao, Y.H., Hersey, A., Ijaz, L. and Butina, D. (2001) "Correlation and prediction of a large blood-brain distribution data set-an LFER study", Eur. J. Med. Chem. 36, 719-730.
7. SYBYL, version 6.8, Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144-2917.
8. MOPAC, version 6.0, QCPE, Department of Chemistry, Indiana University, Bloomington, IN 47405.
9. SYBYL/GASP interface, Ligand-Based Design Manual, Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144-2917.
10. Advanced Chemistry Development Inc., Toronto, ON, Canada, http://www.acdlabs.com
11. Tsar 3D, version 3.3, Accelrys Inc., http://www.accelrys.com
12. Novartis Pharma AG, ChemInformatics, CH-4002, Basel, Switzerland, http://www.daylight.com/meetings/emug00/Ert1/tpsa.html
13. MINITAB, version 14, MINITAB Inc., www.minitab.com
14. Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge, UK,CB2 1EZ.
15. Van de Waterbeemd, H., Camenisch, G., Folkers, G., Chretien, J.R. and Raevsky, O.A. (1998) "Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors", J. Drug Target. 6, 151-165.
16. Feher, M., Sourial, E. and Schmidt, J.M. (2000) "A simple model for the prediction of blood-brain partitioning". Int. J. Pharm. 201, 239-247.
17. Seelig, A. (1998) "A general pattern for substrate recognition by P-glycoprotein", Eur. J. Biochem. 251, 252-261.